Intervention: TEDUGLUTIDE
Trial phase: Phase 2
ATC code: A16AX08
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration

Teduglutide
Eligibility criteria:
Inclusion Criteria:

Men and women age 21-65 with previously diagnosed HIV disease
Stable anti-retroviral therapy (ART) as defined by no changes in ART regimen for >6 months
HIV viral load < 200 copies/mL

To be eligible for colonoscopy procedure, laboratory values that meet the following criteria:

Hemoglobin > 9.0 g/dL
Absolute neutrophil count ≥ 1000/mm3
Platelet count ≥ 100,000/mm3
Prothrombin time (PT) < 1.2 x upper limit of normal (ULN)
Partial thromboplastin time (PTT) < 1.5 x ULN

4. Ability and willingness to give written informed consent and to comply with study requirements

Exclusion Criteria:

History of clinically significant gastrointestinal disease including but not limited to: colon cancer, intestinal obstruction, ulcerative colitis, Crohn's disease, or history of C. difficile within the past 3 months
First-degree relative with history of colon cancer
Active gall bladder, biliary or pancreatic disease
Female subject who is pregnant, nursing or less than 8 weeks post partum.
Use of any immunomodulatory agents within 30 days prior to study enrollment
History of intolerance, sensitivity, allergy or anaphylaxis to benzodiazepines or other narcotics to be used during the colonoscopy or upper endoscopy procedure
Contraindication to beta-blocker (including moderate to severe asthma or heart block) or nitroglycerin use as these drugs are given as part of the standard cardiac CT protocol. Previous allergic reaction to beta blocker or nitroglycerin.
Patients with previous allergic reactions to iodine-containing contrast media
Renal disease or creatinine >1.5 mg/dL (contrast will be administered during CT angiography of the heart)
History of requiring antibiotic prophylaxis for invasive procedures
History of myocardial infarction, decompensated cirrhosis, or any other condition that in the opinion of the investigator will compromise ability to participate in the study
Currently taking anticoagulants including but not limited to: heparin, warfarin (Coumadin), tinzaparin (Innohep), enoxaparin (Lovenox), danaparoid (Orgaran), dalteparin (Fragmin), clopidogrel (Plavix), prophylactic aspirin, and regular NSAID use
Subject taking any of the following medications: statins, systemic steroids (inhaled or nasal steroid therapy is permitted), interleukins, systemic interferons (e.g. local injection of interferon alpha for treatment of human papilloma virus is permitted), systemic chemotherapy including oral chemotherapeutic agents, methotrexate, octreotide, growth hormone, antiarrhythmics including digoxin, antiepileptics, immunosuppressants, vancomycin, rifampin, aminoglycosides, clonidine, prazosin, lithium and ritonavir-boosted lopinavir (Kaletra).
Subject has had two or more endoscopy procedures (sigmoidoscopy, upper endoscopy or colonoscopy) within the past 12 months for clinical purposes or other research studies.
Body weight greater than 300 lbs due to CT scanner table limitations
Active illicit drug use

Patients who report any significant radiation exposure over the course of the year prior to randomization. Significant exposure is defined as:

More than 2 percutaneous coronary interventions (PCI) within 12 months of randomization
More than 2 myocardial perfusion studies within the past 12 months
More than 2 CT angiograms within the past 12 months
Any subjects with history of radiation therapy

Patients already scheduled or being considered for a procedure or treatment

requiring significant radiation exposure (e.g., radiation therapy, PCI, or catheter
ablation of arrhythmia) within 12 months of randomization
History of malignancy
Prior recipient of a HIV vaccine